Morgan Keegan provided color on Medtronic MDT. In a research report published today, Morgan Keegan commented on the problems in some research, which had been sponsored by Medtronic.
In the report, Morgan Keegan states, “Review of 13 InFuse Studies identifies important failings, especially in not identifying
adverse events, but attributing the failures primarily to Medtronic seems to us to be wrong… We are lowering our revenue estimate for InFuse by 15% in FY2012 to account for the
response to this review and other investigations currently underway.”
At the moment, Morgan Keegan has a Market Perform rating and a price target of $43 placed on the company's stock. On Wednesday, Morgan Keegan lost 2.36% of its value to finish the day at $38.09.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in